



ASX Announcement

For immediate release

25 May 2009

CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition

Melbourne, Australia (25 May 2009) – CSL Limited today announced that Managing Director, Dr Brian McNamee, met with U.S. Federal Trade Commission (FTC) Commissioners in Washington DC on 22 May 2009 to discuss CSL's proposed acquisition of Talecris Biotherapeutics, Inc.

Dr McNamee put forward the pro-competitive arguments of CSL's case including significant efficiencies and benefits to consumers resulting from the deal, presented potential remedies which may enable approval, and discussed the consideration of the case by FTC staff.

CSL was informed during the meeting that the FTC staff, after reviewing CSL's case and remedy proposals, have recommended that the Commissioners initiate legal action in the U.S. District Court to block the transaction. A vote and decision by the Commissioners is imminent, likely to be announced by 28 May 2009 Washington time.

CSL will immediately notify the Australian Securities Exchange following advice about the outcome of the US Federal Trade Commissioners' vote.

Media Contacts:

Dr Rachel David
Director, Public Affairs
Ph 61 3 9389 1821
Email: rachel.david@csl.com.au

Tim Duncan
Hinton & Associates
Telephone: +61 (3) 9600-1979
Email: tduncan@hintons.com.au

Investor Contact:

Mark Dehring
Head of Investor Relations
CSL Limited Telephone: +613 9389 2818
Email: mark.dehring@csl.com.au